Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq:
TLRY; TSX: TLRY), a leading global cannabis-lifestyle and
consumer packaged goods company inspiring and empowering the
worldwide community to live their very best life, today announced
that its medical cannabis division, Tilray Medical, launched a new
cannabis education platform,
WeCare-MedicalCannabis, dedicated to providing
resources and educating healthcare practitioners and patients about
medical cannabis.
WeCare-MedicalCannabis provides
science and research-based cannabis content tailored to healthcare
professionals, caregivers, and patients to help them make informed
decisions about medicinal cannabis and assists them along their
path to discovering how medicinal cannabis can support daily
wellness and health. Designed to serve as a one-stop, comprehensive
resource on medical cannabis insights, WeCare-MedicalCannabis is
now available in Germany, France, the United Kingdom, and
Portugal.
Sascha Mielcarek, Managing Director, Tilray
Europe, said, “As global pioneers in medical cannabis, we are aware
of the lack of access to science-based, medical cannabis education.
WeCare-MedicalCannabis was created to bridge that gap and help
provide the needed resources to helping patients, caregivers, and
healthcare professionals with the information they need to make
informed decisions on medicinal cannabis. As cannabis legalization
continues to expand across Europe, Tilray Medical is dedicated to
help provide informed and trusted guidance for those interested in
learning more about medical cannabis.”
Tilray Medical continues to work with leading
patient associations and physician societies, providing value to
those impacted by changes within the medical landscape, and who
serve at the forefront of global health initiatives. By providing
access to educational platforms such as WeCare-MedicalCannabis,
Tilray Medical continues to open and expand its world of
wellbeing.
For more information, please visit our global
platforms at WeCare-MedicalCannabis Germany, WeCare-MedicalCannabis
France, WeCare-MedicalCannabis UK, WeCare-MedicalCannabis
Portugal.
About Tilray Medical Tilray
Medical is dedicated to improving the quality of life for patients
around the world, transforming lives, and fostering dignity for
patients in need through safe and reliable access to a global
portfolio of medicinal cannabis brands. Tilray grew from being one
of the first companies to become an approved licensed producer of
medicinal cannabis in Canada to building the first GMP-certified
cannabis production facilities in Europe, first in Portugal and
later in Germany. Today, Tilray Medical is one of the biggest
suppliers of medicinal cannabis brands to patients, physicians,
hospitals, pharmacies, researchers, and governments, in 20
countries and across five continents.
For more information on Tilray Medical, visit
Tilray Medical Canada, Tilray Medical Australia-New Zealand, Tilray
Medical Europe
About Tilray Brands, Inc.Tilray
Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global
cannabis-lifestyle and consumer packaged goods company with
operations in Canada, the United States, Europe, Australia, and
Latin America that is changing people's lives for the better – one
person at a time. Tilray Brands delivers on this mission by
inspiring and empowering the worldwide community to live their very
best life and by providing access to products that meet the needs
of their mind, body, and soul while invoking wellbeing. Patients
and consumers trust Tilray Brands to deliver a cultivated
experience and health and wellbeing through high-quality,
differentiated brands and innovative products. A pioneer in
cannabis research, cultivation, and distribution, Tilray’s
unprecedented production platform supports over 20 brands in over
20 countries, including comprehensive cannabis offerings,
hemp-based foods, and craft beverages.
For more information on how we open a world of
wellbeing, visit www.tilray.com and follow @tilray.
Forward-Looking
StatementsCertain statements in this communication that
are not historical facts constitute forward-looking information or
forward-looking statements (together, “forward-looking statements”)
under Canadian securities laws and within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, that are intended
to be subject to the “safe harbor” created by those sections and
other applicable laws. Forward-looking statements can be identified
by words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections, or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses, or current
expectations concerning, among other things: expectations regarding
the performance and scale of the Company, including Tilray Medical;
and the Company’s ability to expand its offering to patients
worldwide, including via Tilray Medical. Many factors could cause
actual results, performance, or achievement to be materially
different from any forward-looking statements, and other risks and
uncertainties not presently known to the Company or that the
Company deems immaterial could also cause actual results or events
to differ materially from those expressed in the forward-looking
statements contained herein. For a more detailed discussion of
these risks and other factors, see the most recently filed annual
information form of Tilray and the Annual Report on Form 10-K (and
other periodic reports filed with the SEC) of Tilray made with the
SEC and available on EDGAR. The forward-looking statements included
in this communication are made as of the date of this communication
and the Company does not undertake any obligation to publicly
update such forward-looking statements to reflect new information,
subsequent events, or otherwise unless required by applicable
securities laws.
For further
information:MediaBerrin
Nooratanews@tilray.com
InvestorsRaphael
GrossRaphael.Gross@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Apr 2023 to Apr 2024